

Alcohol Addiction Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/A56485850D3CEN.html>

Date: March 2022

Pages: 132

Price: US\$ 2,000.00 (Single User License)

ID: A56485850D3CEN

Abstracts

Alcohol Addiction Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Alcohol Addiction - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Alcohol Addiction (Central Nervous System) pipeline landscape.

Alcohol addiction refers to a psychological and physical dependency on alcohol. Symptoms include decreased involvement in extracurricular activities, depression, restlessness, inability to control drinking and violent behavior. Risk factors include age, family history and depression and other mental health problems.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Alcohol Addiction - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Alcohol Addiction (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Alcohol Addiction (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Alcohol Addiction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 11, 6, 2, 29, 3 and 2 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 4 and 1 molecules, respectively.

Alcohol Addiction (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Alcohol Addiction (Central Nervous System).

The pipeline guide reviews pipeline therapeutics for Alcohol Addiction (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Alcohol Addiction (Central Nervous System) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Alcohol Addiction (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Alcohol Addiction (Central Nervous System)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Alcohol Addiction (Central Nervous System).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Alcohol Addiction (Central Nervous System) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand

business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

- Introduction
- Global Markets Direct Report Coverage
- Alcohol Addiction - Overview
- Alcohol Addiction - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Alcohol Addiction - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Alcohol Addiction - Companies Involved in Therapeutics Development
- Addex Therapeutics Ltd
- Adial Pharmaceuticals Inc
- Alar Pharmaceuticals Inc
- Aptinyx Inc
- Astellas Pharma Inc
- Astraea Therapeutics LLC
- Avicanna Inc
- AWAKN Life Sciences Corp
- BioCorRx Inc
- Bioprojet SCR
- Ceruvia Lifesciences LLC
- Chronos Therapeutics Ltd
- Clairvoyant Therapeutics Inc
- Clearmind Medicine Inc
- Colorado Research Partners LLC
- Confluence Pharmaceuticals LLC
- Corcept Therapeutics Inc
- Curemark LLC
- Cybin Inc
- Eli Lilly and Co
- Journey Colab Corp
- Kinnov Therapeutics

Kinoxis Therapeutics Pty Ltd
Kyorin Pharmaceutical Co Ltd
Laboratorio Farmaceutico CT Srl
Lohocla Research Corp
Mapreg SAS
Mind Medicine MindMed Inc
Montisera Ltd
Naprogenix Inc
Neuroepigenix LLC
Novo Nordisk AS
Omeros Corp
Opiant Pharmaceuticals Inc
Orphomed Inc
Osmotica Pharmaceutical Corp
Palisades Therapeutics
Pfizer Inc
Protagenic Therapeutics Inc
Psilera Inc
Sage Therapeutics Inc
SK Biopharmaceuticals Co Ltd
Sobrero Pharma AB
South Plains Biotechnology Inc
Syntropharma Ltd
Tonix Pharmaceuticals Holding Corp
VM Discovery Inc
Whan In Pharm Co Ltd
Zynerba Pharmaceuticals Inc
Alcohol Addiction - Drug Profiles
(cyproheptadine hydrochloride + prazosin hydrochloride) - Drug Profile
Product Description
Mechanism Of Action
History of Events
(varenicline tartrate + bupropion hydrochloride) SR - Drug Profile
Product Description
Mechanism Of Action
acamprosate calcium SR - Drug Profile
Product Description
Mechanism Of Action
History of Events

ADX-71441 - Drug Profile

Product Description

Mechanism Of Action

History of Events

ALA-2000 - Drug Profile

Product Description

Mechanism Of Action

arbaclofen ER - Drug Profile

Product Description

Mechanism Of Action

ASP-8062 - Drug Profile

Product Description

Mechanism Of Action

History of Events

AT-1001 - Drug Profile

Product Description

Mechanism Of Action

BICX-101 SR - Drug Profile

Product Description

Mechanism Of Action

History of Events

BICX-102 - Drug Profile

Product Description

Mechanism Of Action

History of Events

BP-1.3656B - Drug Profile

Product Description

Mechanism Of Action

History of Events

brexanolone - Drug Profile

Product Description

Mechanism Of Action

History of Events

CM-1212 - Drug Profile

Product Description

Mechanism Of Action

CMND-100 - Drug Profile

Product Description

Mechanism Of Action

History of Events

CTDP-002 - Drug Profile

Product Description

Mechanism Of Action

History of Events

CYB-003 - Drug Profile

Product Description

Mechanism Of Action

History of Events

D-15 - Drug Profile

Product Description

Mechanism Of Action

DCRALDH-2 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Drugs to Inhibit Fructokinase for Alcohol Addiction - Drug Profile

Product Description

Mechanism Of Action

History of Events

GET-73 - Drug Profile

Product Description

Mechanism Of Action

History of Events

ibudilast - Drug Profile

Product Description

Mechanism Of Action

History of Events

JOUR-001 - Drug Profile

Product Description

Mechanism Of Action

JR-220 - Drug Profile

Product Description

Mechanism Of Action

History of Events

ketamine - Drug Profile

Product Description

Mechanism Of Action

History of Events

KNX-100 - Drug Profile

Product Description

Mechanism Of Action

MAP-4343 - Drug Profile

Product Description

Mechanism Of Action

midomafetamine - Drug Profile

Product Description

Mechanism Of Action

History of Events

mifepristone - Drug Profile

Product Description

Mechanism Of Action

History of Events

MQ-221 - Drug Profile

Product Description

Mechanism Of Action

naltrexone - Drug Profile

Product Description

Mechanism Of Action

naltrexone hydrochloride - Drug Profile

Product Description

Mechanism Of Action

History of Events

naltrexone hydrochloride - Drug Profile

Product Description

Mechanism Of Action

History of Events

naltrexone LA - Drug Profile

Product Description

Mechanism Of Action

History of Events

Nezavist - Drug Profile

Product Description

Mechanism Of Action

History of Events

NYPRG-101 - Drug Profile

Product Description

Mechanism Of Action

NYX-783 - Drug Profile

Product Description

Mechanism Of Action

History of Events

odelepran - Drug Profile

Product Description

Mechanism Of Action

History of Events

OMS-527 - Drug Profile

Product Description

Mechanism Of Action

History of Events

ondansetron hydrochloride - Drug Profile

Product Description

Mechanism Of Action

History of Events

ORP-106 - Drug Profile

Product Description

Mechanism Of Action

PF-05190457 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Pharmacotherapy for Alcohol Use Disorder - Drug Profile

Product Description

Mechanism Of Action

History of Events

PSIL-002 - Drug Profile

Product Description

Mechanism Of Action

psilocybin - Drug Profile

Product Description

Mechanism Of Action

psilocybin - Drug Profile

Product Description

Mechanism Of Action

PT-00114 - Drug Profile

Product Description

Mechanism Of Action

History of Events

PT-150 - Drug Profile

Product Description

Mechanism Of Action

History of Events

RC-132 - Drug Profile

Product Description

Mechanism Of Action

RTI-1395133 - Drug Profile

Product Description

Mechanism Of Action

SKL-10406 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecule to Antagonize Mu Opioid Receptor for Drug Abuse, Alcohol Addiction and OIC - Drug Profile

Product Description

Mechanism Of Action

Small Molecule to Antagonize NMDA Receptor and Block Sodium Channels for CNS disorders - Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules for Alcohol Use Disorder - Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules for Psychiatric Disorders - Drug Profile

Product Description

Mechanism Of Action

Small Molecules To Agonize Nociceptin Receptors For Alcohol Addiction - Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Antagonize GABAA1 for Alcohol Addiction and Anxiety - Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Antagonize Glucocorticoid Receptor II for Alcohol Dependence -

Drug Profile

Product Description

Mechanism Of Action

TNX-102 - Drug Profile

Product Description

Mechanism Of Action

VMD-2202 - Drug Profile

Product Description

Mechanism Of Action

History of Events

WIL-1903 - Drug Profile

Product Description

Mechanism Of Action

zolonicant hydrochloride - Drug Profile

Product Description

Mechanism Of Action

History of Events

Alcohol Addiction - Dormant Projects

Alcohol Addiction - Discontinued Products

Alcohol Addiction - Product Development Milestones

Featured News & Press Releases

Mar 17, 2022: Clearmind Medicine announces positive results on CMND-100 trials

Feb 28, 2022: MediciNova announces MN-166 (ibudilast) identified as potential beneficial pharmacotherapy for treatment of degenerative cervical myelopathy in Global Spine Journal

Feb 24, 2022: Adial Pharmaceuticals announces completion of last patient, last visit in its ONWARD phase 3 trial of AD04 for the treatment of patients with alcohol use disorder

Feb 22, 2022: MediciNova announces MN-166 (ibudilast) identified as promising pharmacotherapy for alcohol use disorder in drugs

Jan 28, 2022: Clearmind Medicine partners with Dr. Gabor Mate to discuss alcohol use disorder and trauma in a special virtual Event on February

Jan 27, 2022: MediciNova receives a notice of intention to grant for a new patent covering MN-166 (ibudilast) for the treatment of alcohol use disorder in Europe

Jan 20, 2022: Opiant Pharmaceuticals announces first patient dosed in phase 2 trial of OPNT002, nasal Naltrexone, for alcohol use disorder

Jan 20, 2022: Clairvoyant Therapeutics receives approval in Canada to initiate a world-leading psilocybin trial for treatment of alcohol use disorder

Jan 19, 2022: Awakn Life Sciences signs MOU With MAPS

Jan 11, 2022: Awakn announces positive results from phase II A/B clinical trial

Dec 08, 2021: Cybin confirms scientific advice meeting with UK Medical and Healthcare Products Regulatory Agency for lead candidate CYB003 for the treatment of major depressive disorder and alcohol use disorder

Nov 16, 2021: Awakn Life Sciences signs MOU with NHS (Devon Partnership NHS Trust) and University of Exeter with a view of increasing access to psychedelic-assisted psychotherapy in the UK

Nov 08, 2021: Cybin announces positive CYB003 data demonstrating significant advantages over oral psilocybin for treatment of mental health

Nov 04, 2021: Awakn Life Sciences announces the findings from phase II A/B study are to be published In American Journal Of Psychiatry

Oct 26, 2021: Clearmind signs development and supply agreement to produce its drug candidate MEAI psychedelic molecule with Aragen Life Sciences

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Alcohol Addiction, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Number of Products under Development by Companies, 2022 (Contd..2)
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Target, 2022 (Contd..1)
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Alcohol Addiction - Pipeline by Addex Therapeutics Ltd, 2022
Alcohol Addiction - Pipeline by Adial Pharmaceuticals Inc, 2022
Alcohol Addiction - Pipeline by Alar Pharmaceuticals Inc, 2022
Alcohol Addiction - Pipeline by Aptinyx Inc, 2022
Alcohol Addiction - Pipeline by Astellas Pharma Inc, 2022
Alcohol Addiction - Pipeline by Astraea Therapeutics LLC, 2022
Alcohol Addiction - Pipeline by Avicanna Inc, 2022
Alcohol Addiction - Pipeline by AWAKN Life Sciences Corp, 2022
Alcohol Addiction - Pipeline by BioCorRx Inc, 2022
Alcohol Addiction - Pipeline by Bioprojet SCR, 2022
Alcohol Addiction - Pipeline by Ceruvia Lifesciences LLC, 2022
Alcohol Addiction - Pipeline by Chronos Therapeutics Ltd, 2022
Alcohol Addiction - Pipeline by Clairvoyant Therapeutics Inc, 2022
Alcohol Addiction - Pipeline by Clearmind Medicine Inc, 2022
Alcohol Addiction - Pipeline by Colorado Research Partners LLC, 2022
Alcohol Addiction - Pipeline by Confluence Pharmaceuticals LLC, 2022
Alcohol Addiction - Pipeline by Corcept Therapeutics Inc, 2022
Alcohol Addiction - Pipeline by Curemark LLC, 2022
Alcohol Addiction - Pipeline by Cybin Inc, 2022
Alcohol Addiction - Pipeline by Eli Lilly and Co, 2022

Alcohol Addiction - Pipeline by Journey Colab Corp, 2022
Alcohol Addiction - Pipeline by Kinnov Therapeutics, 2022
Alcohol Addiction - Pipeline by Kinaxis Therapeutics Pty Ltd, 2022
Alcohol Addiction - Pipeline by Kyorin Pharmaceutical Co Ltd, 2022
Alcohol Addiction - Pipeline by Laboratorio Farmaceutico CT Srl, 2022
Alcohol Addiction - Pipeline by Lohocla Research Corp, 2022
Alcohol Addiction - Pipeline by Mapreg SAS, 2022
Alcohol Addiction - Pipeline by Mind Medicine MindMed Inc, 2022
Alcohol Addiction - Pipeline by Montisera Ltd, 2022
Alcohol Addiction - Pipeline by Naprogenix Inc, 2022
Alcohol Addiction - Pipeline by Neuroepigenix LLC, 2022
Alcohol Addiction - Pipeline by Novo Nordisk AS, 2022
Alcohol Addiction - Pipeline by Omeros Corp, 2022
Alcohol Addiction - Pipeline by Opiant Pharmaceuticals Inc, 2022
Alcohol Addiction - Pipeline by Orphomed Inc, 2022
Alcohol Addiction - Pipeline by Osmotica Pharmaceutical Corp, 2022
Alcohol Addiction - Pipeline by Palisades Therapeutics, 2022
Alcohol Addiction - Pipeline by Pfizer Inc, 2022
Alcohol Addiction - Pipeline by Protagenic Therapeutics Inc, 2022
Alcohol Addiction - Pipeline by Psilera Inc, 2022
Alcohol Addiction - Pipeline by Sage Therapeutics Inc, 2022
Alcohol Addiction - Pipeline by SK Biopharmaceuticals Co Ltd, 2022
Alcohol Addiction - Pipeline by Sobrera Pharma AB, 2022
Alcohol Addiction - Pipeline by South Plains Biotechnology Inc, 2022
Alcohol Addiction - Pipeline by Syntropharma Ltd, 2022
Alcohol Addiction - Pipeline by Tonix Pharmaceuticals Holding Corp, 2022
Alcohol Addiction - Pipeline by VM Discovery Inc, 2022
Alcohol Addiction - Pipeline by Whan In Pharm Co Ltd, 2022
Alcohol Addiction - Pipeline by Zynerba Pharmaceuticals Inc, 2022
Alcohol Addiction - Dormant Projects, 2022
Alcohol Addiction - Dormant Projects, 2022 (Contd..1)
Alcohol Addiction - Dormant Projects, 2022 (Contd..2)
Alcohol Addiction - Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Alcohol Addiction, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

I would like to order

Product name: Alcohol Addiction Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/A56485850D3CEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A56485850D3CEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

